Bacopasaponin C
(Synonyms: 假马齿苋皂苷C) 目录号 : GC35456
A triterpenoid saponin with diverse biological activities
Cas No.:178064-13-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Bacopasaponin C is a triterpenoid saponin originally isolated from B. monniera that has diverse biological activities.1,2,3 It inhibits the ATPase activity of P-glycoprotein (IC50 = 57.83 ?g/ml).4 Bacopasaponin C inhibits scopolamine-induced impairments in spatial memory in the Morris water maze and memory retrieval in the step-down test in mice when administered at a dose of 50 mg/kg.1 It also decreases the time mice spent immobile in the forced swim and tail suspension tests, indicating antidepressant-like activity.2 Bacopasaponin C reduces the spleen parasite load in a hamster model of leishmaniasis when administered as a free compound or in liposomal, niosomal, microencapsulated, or nanocapsulated forms.3
1.Zhou, Y., Peng, L., Zhang, W.-D., et al.Effect of triterpenoid saponins from Bacopa monniera on scopolamine-induced memory impairment in micePlanta Med.75(6)568-574(2009) 2.Zhou, Y., Shen, Y.-H., Zhang, C., et al.Triterpene saponins from Bacopa monnieri and their antidepressant effects in two mice modelsJ. Nat. Prod.70(4)652-655(2007) 3.Sinha, J., Raay, B., Das, N., et al.Bacopasaponin C: Critical evaluation of anti-leishmanial properties in various delivery modesDrug Deliv.9(1)55-62(2002) 4.Singh, R., Rachumallu, R., Bhateria, M., et al.In vitro effects of standardized extract of Bacopa monniera and its five individual active constituents on human P-glycoprotein activityXenobiotica45(8)741-749(2015)
| Cas No. | 178064-13-6 | SDF | |
| 别名 | 假马齿苋皂苷C | ||
| 分子式 | C46H74O17 | 分子量 | 899.07 |
| 溶解度 | Methanol: soluble | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1123 mL | 5.5613 mL | 11.1226 mL |
| 5 mM | 0.2225 mL | 1.1123 mL | 2.2245 mL |
| 10 mM | 0.1112 mL | 0.5561 mL | 1.1123 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Bacopasaponin C: critical evaluation of anti-leishmanial properties in various delivery modes
Drug Deliv 2002 Jan-Mar;9(1):55-62.PMID:11839209DOI:10.1080/107175402753413181.
Bacopasaponin C, an indigenous glycoside, was isolated from Indian medicinal plant Bacopa monniera (b. brahmi) and was tested for antileishmanial properties both in free and in various delivery modes, e.g., niosomes, microspheres, and nanoparticles that are used now as alternatives to more commonly used liposomes. The different vesicles were prepared by published protocols. The percent intercalation of Bacopasaponin C in liposomes, niosomes, and micropspheres determined at its absorption maximal (lambda(max) = 238 nm, epsilon = 8.6 x 10(3) M(-1) x cm(-1)) was found to be 30; for nanoparticles it was 50. At equivalent dose of 1.75 mg/kg body weight, every third day for a total of 6 doses in 15 days, Bacopasaponin C in all the vesicular forms was found to be very active. An inverse linear relationship between the efficacy and the size of the vesicles was established. As analyzed from tissue histology, blood pathology, and specific tests related to normal liver and kidney functions, Bacopasaponin C in each of the four vesicular forms was found to be without any side effects. Thus, because of its indigenous origin and non-toxic nature, Bacopasaponin C could very well be considered for application in the clinic through these alternative delivery modes.
Bacopa monnieri for Disorders Affecting Brain: Current Perspectives
Curr Top Med Chem 2022;22(23):1909-1929.PMID:35043757DOI:10.2174/1568026622666220119111538.
Bacopa monnieri (BM) is of immense therapeutic potential in today's world. This review is aimed to project the beneficial role of BM in disorders affecting the brain, including Alzheimer's disease, Parkinson's disease, stroke, epilepsy, and depression. The active constituents and metabolites responsible for the effects of BM could be bacoside A and B, bacopaside I and II, Bacopasaponin C, betulinic acid, asiatic acid, loliolide, ebelin lactone, and quercetin. The mechanistic role of BM in brain disorders might be related to its ability to modulate neurotransmission, neurogenesis, neuronal/ glial plasticity, intracellular signaling, epigenetics, cerebral blood flow, energy metabolism, protein folding, endoplasmic reticulum stress, neuroendocrine system, oxidative stress, inflammation, and apoptosis. We have also discussed CDRI-08, clinical trials, safety, emerging formulation technologies, as well as BM combinations, and dietary supplements. To propel the clinical translation of BM in disorders affecting the brain, strategies to improve brain delivery via novel formulations and integration of the preclinical findings into large and well-defined clinical trials, in appropriate age groups and sex, specifically in the patient population against existing medications as well as placebo, are essentially required.
Two new triterpenoid glycosides from Bacopa monnieri and their cytotoxic activity
Nat Prod Res 2022 Oct 14;1-7.PMID:36239487DOI:10.1080/14786419.2022.2132498.
Using combined chromatographic methods, two new triterpenoid glycosides, bacopasaponin K (1) and bacopasaponin L (2), along with eight known compounds, bacopaside IV (3), bacopaside VII (4), bacopasaponin E (5), bacoside A3 (6), bacopasaponin F (7), Bacopasaponin C (8), bacopaside I (9), and bacopaside II (10) were isolated from the methanol extract of the Bacopa monnieri. Their structures were elucidated by 1D-, 2D-NMR spectroscopic analysis, HR-ESI-MS and comparing with the NMR data reported in the literature. All these compounds were evaluated for their cytotoxic activity using the cell counting kit-8 (CCK-8) assay. Compounds 4, 6, 8, and 10 exhibited potential cytotoxic effects against human lung cancer cells (PC9) and human colon cancer cells (SW620).
Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Curr Neuropharmacol 2019;17(5):438-446.PMID:29676230DOI:10.2174/1570159X16666180419123022.
Bacopa monnieri, commonly known as Brahmi, has been extensively used as a neuromedicine for various disorders such as anxiety, depression and memory loss. Chemical characterization studies revealed the major active constituents of the herb as the triterpenoid saponins, bacosides. Bacoside A, the vital neuroprotective constituent, is composed of four constituents viz., bacoside A3, bacopaside II, jujubogenin isomer of Bacopasaponin C (bacopaside X) and Bacopasaponin C. B. monnieri extracts as well as bacosides successfully establish a healthy antioxidant environment in various tissues especially in the liver and brain. Free radical scavenging, suppression of lipid peroxidation and activation of antioxidant enzymes by bacosides help to attain a physiological state of minimized oxidative stress. The molecular basis of neuroprotective activity of bacosides is attributed to the regulation of mRNA translation and surface expression of neuroreceptors such as AMPAR, NMDAR and GABAR in the various parts of the brain. Bioavailability as well as binding of neuroprotective agents (such as bacosides) to these receptors is controlled by the Blood Brain Barrier (BBB). However, nano conversion of these drug candidates easily resolves the BBB restriction and carries a promising role in future therapies. This review summarizes the neuroprotective functions of B. monnieri extracts as well as its active compounds (bacoside A, bacopaside I) and the molecular mechanisms responsible for these pharmacological activities.
Enhanced production of Bacopa saponins by repeated batch strategy in bioreactor
Bioprocess Biosyst Eng 2022 May;45(5):829-841.PMID:35119526DOI:10.1007/s00449-022-02700-4.
Cultivation of cell suspension culture of Bacopa monnieri targeting the production of bacosides was explored in a 5-l stirred tank reactor using statistically optimized conditions. The bioreactor cultivation conditions were modified and this led to profuse biomass growth (2.81 ± 0.20 g/l) and total bacosides (1.26 ± 0.23 mg/g in cells and 0.60 ± 0.11 mg/l in fermenter broth) production in 9 days. The values of static volumetric mass transfer coefficient (kLa), dimensionless mixing time (Nm) were measured in the bioreactor. The culture grew efficiently and produced enhanced amount of bacoside A (5.59 ± 0.41 mg/g total bacosides in cells and 3.12 ± 0.13 mg/l in the fermenter broth) using one cycle of repeated batch strategy adopted in the bioreactor for 15 days. The intracellular concentration of bacoside A3 (1.18 ± 0.11 mg/g), bacopaside II (2.09 ± 0.35 mg/g), bacopaside X (0.79 ± 0.17 mg/g) and Bacopasaponin C (2.24 ± 0.23 mg/g) were significantly higher in repeated batch as compared to batch bioreactor cultivation. The yield of total bacosides in the fermenter broth was 5-times higher in repeated batch as compared to batch cultivation. This strategy can be helpful for the enhanced production of other valuable triterpenoid saponins.